The American Journal of Medicine
Volume 122, Issue 6 , Pages 581.e1-581.e10 , June 2009

Comprehensive Meta-Analysis on Drug-Eluting Stents versus Bare-Metal Stents during Extended Follow-up

  • Henri Roukoz, MD

      Affiliations

    • Department of Cardiovascular Medicine, University of Minnesota, Minneapolis
    • ,
  • Anthony A. Bavry, MD, MPH

      Affiliations

    • Division of Cardiovascular Medicine, University of Florida, Gainesville
    • ,
  • Michael L. Sarkees, MD

      Affiliations

    • Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Girish R. Mood, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Dharam J. Kumbhani, MD, SM

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Mark G. Rabbat, MD

      Affiliations

    • Cardiovascular Institute, Loyola University Medical Center, Maywood, Ill
    • ,
  • Deepak L. Bhatt, MD, MPH

      Affiliations

    • VA Boston Healthcare System and Brigham and Women's Hospital, Boston, Mass
    • Corresponding Author InformationRequests for reprints should be addressed to Deepak L. Bhatt, MD, MPH, VA Boston Healthcare System, Integrated Interventional Cardiovascular Program, Brigham and Women's Hospital and the VA Boston Healthcare System, TIMI Study Group, Harvard Medical School, 75 Francis St., PBB-146, Boston, MA, 02115

References 

  1. Babapulle MN, Joseph L, Belisle P, et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004;364:583–591
  2. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008
  3. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030–1039
  4. Diaz de la Llera LS, Ballesteros S, Nevado J, et al. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J. 2007;154:164e1-164e6
  5. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355:1093–1104
  6. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355:1105–1113
  7. Menichelli M, Parma A, Pucci E, et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol. 2007;49:1924–1930
  8. Tierala I, Syväänne M, Kupari M. The HAAMU-STENT study. http://www.tctmd.com/Show.aspx?id=56036Accessed September 22, 2008
  9. Chechi T, Vittori G, Biondi Zoccai GG, et al. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol. 2007;20:282–291
  10. Gao H, Yan HB, Zhu XL, et al. Firebird sirolimus eluting stent versus bare mental stent in patients with ST-segment elevation myocardial infarction. Chin Med J (Engl). 2007;120:863–867
  11. Valgimigli M, Campo G, Arcozzi C, et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. J Am Coll Cardiol. 2007;50:138–145
  12. van der Hoeven BL, Liem SS, Jukema JW, et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol. 2008;51:618–626
  13. FDA public health notification: information for physicians on subacute thromboses (SAT) and hypersensitivity reactions with use of the Cordis Cypher coronary stent (Issued October 29, 2003). http://www.fda.gov/cdrh/safety/cypher.htmlAccessed September 22, 2008
  14. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119:1056–1061
  15. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–1019
  16. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27:2784–2814
  17. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937–948
  18. Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358:342–352
  19. Applegate RJ, Sacrinty MT, Kutcher MA, et al. “Off-label” stent therapy 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2008;51:607–614
  20. Mauri L. Long-term clinical outcomes following drug-eluting and bare metal stenting in Massachusetts. http://www.cardiosource.com/rapidnewssummaries/index.asp?EID=30&DoW=Sun&SumID=286Accessed April 10, 2008
  21. Mauri L, Silbaugh TS, Pallav G, et al. Drug-eluting or bare metal stents for acute myocardial infarction. N Engl J Med. 2008;359:1330–1342
  22. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38–42
  23. Grube E, Silber S, Hauptmann KE, et al. TAXUS I 5 year follow-up. http://www.attendeeinteractive.com/Shows/TCT0601/Images/Documents/ATT_223_1599.pdfAccessed April 10, 2008
  24. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788–794
  25. Grube E, Silber S, Hauptmann KE, et al. Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Am J Cardiol. 2005;96:79–82
  26. Colombo A, Banning A, Silbert S, et al. TAXUS II 3-year clinical results: durability of the benefit of polymer-based, paclitaxel eluting stents in the treatment of de novo coronary artery lesions. Am J Cardiol. 2005;96(Suppl 7A):129H
  27. Colombo A. TAXUS II 4 year follow-up. http://www.attendeeinteractive.com/Shows/TCT0601/Images/Documents/ATT_95007_1616.pdfAccessed April 10, 2008
  28. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231
  29. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942–1947
  30. Stone GW, Ellis SG. TAXUS IV final 5-year outcomes. http://www.bostonscientific.com/templatedata/imports/collateral/AboutBSC/bsc_TAXUSIV_5yr_102207.pdfAccessed September 22, 2008
  31. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294:1215–1223
  32. Ellis SG. TAXUS V 1 year follow-up. http://www.tctmd.com/csportal/appmanager/tctmd/descoe?_nfpb=true&_pageLabel=DESCenterContent&hdCon=1352453Accessed April 10, 2008
  33. Ellis SG, Cannon LA, Mann T, et al. TAXUS V 2 year follow-up. http://www.attendeeinteractive.com/Shows/TCT0601/Images/Documents/ATT_229_1626.pdfAccessed April 10, 2008
  34. Grube E. TAXUS VI 9 month follow-up. http://www.tctmd.com/csportal/appmanager/tctmd/descoe?_nfpb=true%26_pageLabel=DESCenterContent%26hdCon=958541Accessed April 10, 2008
  35. Dawkins KD. TAXS VI 3 year follow-up. http://www.attendeeinteractive.com/Shows/TCT0601/Images/Documents/ATT_195_1608.pdfAccessed April 10, 2008
  36. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  37. Holmes DR, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004;109:634–640
  38. Weisz G, Leon MB, Holmes DR, et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol. 2006;47:1350–1355
  39. Stone G. SIRIUS 4 year follow-up. http://www.tctmd.com/csportal/appmanager/tctmd/main?_nfpb=true&_pageLabel=TCTMDContent&hdCon=1390211Accessed April 10, 2008
  40. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110–1115
  41. Schampaert E, Cohen EA, Reeves F, et al. C-SIRIUS 2 year follow-up [Abstract]. Am J Cardiol. 2005;96(Suppl 7A):53H
  42. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093–1099
  43. Schampaert E, Schofer J, Breithardt G, et al. A European and Canadian multicenter randomized, double-blind trial of the sirolimus-eluting stent (SES) in patients with de novo native coronary artery lesions (NEW-SIRIUS): 5-year clinical outcomes. Circulation. 2007;116(II):466
  44. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780
  45. Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007;50:1299–1304
  46. Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA. 2004;292:2727–2734
  47. Kelbaek H, Thuesen L, Helqvist S, et al. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol. 2006;47:449–455
  48. Kelbæk H, Thuesen L, Helqvist S, et al. SCANDSTENT 1 year follow-up. http://www.tctmd.com/csportal/appmanager/tctmd/descoe?_nfpb=true&_pageLabel=DESCenterContent&hdCon=1430615Accessed April 10, 2008
  49. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation. 2005;112:2175–2183
  50. Quevedo PJ, Sabate M, Azcona L, et al. DIABETES I 2 year follow-up. http://www.escardio.org/knowledge/congresses/abol/presentation?id=40800Accessed September 22, 2008
  51. Chan C, Zambahari R, Kaul U, et al. Outcomes in diabetic patients with multivessel disease and long lesions: results from the DECODE STUDY. Am J Cardiol. 2005;96(Suppl 7A):31H
  52. Pache J, Dibra A, Mehilli J, et al. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J. 2005;26:1262–1268
  53. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA. 2005;293:2109–2117
  54. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet. 2005;366:921–929
  55. Kaiser C. BASKET 18 month follow-up. http://www.escardio.org/knowledge/OnlineLearning/slides/world-congress-2006/Kaiser_FP4825.htmAccessed September 22, 2008
  56. Erglis A, Narbute I, Kumsars I, et al. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. J Am Coll Cardiol. 2007;50:491–497
  57. Valgimigli M. Three-year clinical follow-up after sirolimus-eluting versus bare metal stent implantation assisted by systematic glycoprotein IIb/IIIa infusion in patients with myocardial infarction. http://www.escardio.org/NR/rdonlyres/EB7965FE-44B8-47E0-A8A9-3385199E15DD/0/1023_Valgimigli_CTU1.pdfAccessed September 22, 2008
  58. Suttorp MJ, Laarman GJ, Rahel BM, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation. 2006;114:921–928
  59. Silber S, Colombo A, Banning AP, et al. In: Long-term safety and clinical efficacy in the slow- and moderate-release polymer-based, paclitaxel-eluting TAXUS stent: final 5-year results of the TAXUS II trial. AHA Scientific Sessions 2007, Orlando, FL. 2007;poster presentation
  60. Maresta A, Varani E, Balducelli M, et al. In: Sirolimus-eluting stent versus bare-metal stent in diabetic patients: results of the Italian multicenter, randomized “dessert” study. AHA Scientific Sessions 2007, Orlando, FL. 2007;poster presentation
  61. Schampaert E, Schofer J, Breithardt G, et al. In: A European and Canadian multicenter randomized, double-blind trial of the sirolimus-eluting stent (SES) in patients with de novo native coronary artery lesions (NEW-SIRIUS): 5-year clinical outcomes. AHA Scientific Sessions 2007, Orlando, FL. 2007;poster presentation
  62. Kirtane AJ. On-label CYPHER and TAXUS randomized trial with 5-year follow-up. http://www.tctmd.com/csportal/appmanager/tctmd/descoe?_nfpb=true&_pageLabel=DESCenterContent&hdCon=1518612Accessed April 10, 2008
  63. Baumgart D, Klauss V, Baer F, et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol. 2007;50:1627–1634
  64. Kumbhani DJ, Bavry AA, Kamdar AR, et al. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials. Am Heart J. 2008;155:640–647
  65. Stone GW, Ellis SG, Colombo A, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. 2007;115:2842–2847
  66. Nayak AK, Kawamura A, Nesto RW, et al. Myocardial infarction as a presentation of clinical in-stent restenosis. Circ J. 2006;70:1026–1029
  67. Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J. 2006;151:1260–1264
  68. Bossi I, Klersy C, Black AJ, et al. In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol. 2000;35:1569–1576
  69. Walters DL, Harding SA, Walsh CR, et al. Acute coronary syndrome is a common clinical presentation of in-stent restenosis. Am J Cardiol. 2002;89:491–494
  70. Doyle B, Rihal CS, O'Sullivan CJ, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation. 2007;116:2391–2398
  71. Corbett SJ, Cosgrave J, Melzi G, et al. Patterns of restenosis after drug-eluting stent implantation: Insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents. Eur Heart J. 2006;27:2330–2337
  72. Kastrati A, Dibra A, Mehilli J, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation. 2006;113:2293–2300
  73. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation. 2005;111:2257–2273
  74. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519–1521
  75. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989–997
  76. Daemen J, Tanimoto S, Garcia-Garcia HM, et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol. 2007;99:1027–1032
  77. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667–678
  78. Awata M, Kotani JI, Uematsu M, et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation (Comparison with bare-metal stents). Circulation. 2007;116:910–916
  79. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516
  80. Bavry AA, Bhatt DL. A review on the appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet. 2008;371:2134–2143

 Funding: None.

 Conflicts of interest: Dr. Deepak Bhatt discloses the following relationships: Research Grants (directly to the institution): Bristol Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi Aventis, The Medicines Company; Honoraria (donated to non-profits for >2 years): Astra Zeneca, Bristol Myers Squibb, Centocor, Daiichi-Sankyo, Eisai, Eli Lilly, Glaxo Smith Kline, Millennium, Paringenix, PDL, Sanofi Aventis, Schering Plough, The Medicines Company, tns Healthcare; Speaker's bureau (>2 years ago): Bristol Myers Squibb, Sanofi Aventis, The Medicines Company; Consultant/Advisory Board (waived or donated to non-profits for >2 years): Arena, Astellas, Astra Zeneca, Bristol Myers Squibb, Cardax, Centocor, Cogentus, Daiichi-Sankyo, Eisai, Eli Lilly, Glaxo Smith Kline, Johnson & Johnson, McNeil, Medtronic, Millennium, Molecular Insights, Otsuka, Paringenix, PDL, Philips, Portola, Sanofi Aventis, Schering Plough, Scios, Takeda, The Medicines Company, tns Healthcare, Vertex; Expert testimony about clopidogrel (>2 years ago; the compensation was donated to a non-profit organization).

 Dr. Anthony Bavry discloses the following relationships: Honoraria from Access Closure and Boston Scientific.

 Authorship: All authors had access to the data and a role in writing.

PII: S0002-9343(09)00112-0

doi: 10.1016/j.amjmed.2008.12.019

The American Journal of Medicine
Volume 122, Issue 6 , Pages 581.e1-581.e10 , June 2009

Article Tools

* Image Usage & Resolution